Loading patent…
AssigneeYESA RESEARCH AND DEVELOPMENT CO. LTD. at the Weizmann Institute of Science
InventorsMichal Eisenbach-Schwartz, Jonathan Kipnis
Estimating the term…
Compositions and methods for modulation of the suppressive activity of CD4+CD25+regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff) are provided. An agent selected from: (i) dopamine; (ii) a dopamine precursor; (iii) a D1-R agonist; (iv) a D2-R antagonist; (v) a combination of (i) and (ii); or (vi) a combination of (i), (ii) or (iii) with (iv), down-regulates the suppressive activity of Treg and is useful for treatment of cancer. An agent selected from (i) a dopamine D2-R agonist, (ii) a dopamine D1-R antagonist, and (iii) a combination of (i) and (ii), up-regulates the suppressive activity of Treg and is useful for treatment of an autoimmune disease or for controlling graft rejection in tissue/organ transplantation.
A method for modulating the suppressive effect of CD4+CD25+ regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff), which comprises administering to an individual in need an agent selected from the group consisting of dopamine, a dopamine precursor, a dopamine agonist, a dopamine antagonist, and a combination thereof.
A method for treatment of cancer,
A method for treatment of an autoimmune disease, said method comprising administering to an individual suffering from an autoimmune disease an agent that up-regulates the suppressive activity of CD4+CD25++regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff), wherein said agent is selected from the group consisting of (i) a dopamine D2-R agonist or a pharmaceutically acceptable salt thereof, a dopamine D1-R antagonist or a pharmaceutically acceptable salt thereof, and (iii) a combination of (i) and (ii).
A method for controlling graft rejection in an individual undergoing tissue or organ transplantation which comprises administering to said individual an agent that up-regulates the suppressive activity of CD4+CD25+ regulatory T cells (Treg) on CD4+CD25− effector T cells (Teff), wherein said agent is selected from the group consisting of (i) a dopamine D2-R agonist or a pharmaceutically acceptable salt thereof, a dopamine D1-R antagonist or a pharmaceutically acceptable salt thereof, and a combination of (i) and (ii).
48-122. (canceled)
Dependencies are inferred from the claim text.